BRPI1008566A8 - métodos e composições para o diagnóstico e tratamento de câncer - Google Patents
métodos e composições para o diagnóstico e tratamento de câncerInfo
- Publication number
- BRPI1008566A8 BRPI1008566A8 BRPI1008566A BRPI1008566A BRPI1008566A8 BR PI1008566 A8 BRPI1008566 A8 BR PI1008566A8 BR PI1008566 A BRPI1008566 A BR PI1008566A BR PI1008566 A BRPI1008566 A BR PI1008566A BR PI1008566 A8 BRPI1008566 A8 BR PI1008566A8
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- treatment
- methods
- cancer diagnosis
- diagnosis
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15415909P | 2009-02-20 | 2009-02-20 | |
EP09002458A EP2221063A1 (en) | 2009-02-20 | 2009-02-20 | Methods and compositions for diagnosis and treatment of cancer |
PCT/EP2010/001035 WO2010094490A1 (en) | 2009-02-20 | 2010-02-18 | Methods and compositions for diagnosis and treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI1008566A2 BRPI1008566A2 (pt) | 2017-06-06 |
BRPI1008566A8 true BRPI1008566A8 (pt) | 2018-01-02 |
Family
ID=40594202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1008566A BRPI1008566A8 (pt) | 2009-02-20 | 2010-02-18 | métodos e composições para o diagnóstico e tratamento de câncer |
Country Status (14)
Country | Link |
---|---|
US (1) | US9637548B2 (pt) |
EP (3) | EP2221063A1 (pt) |
JP (2) | JP5809067B2 (pt) |
KR (1) | KR20110128315A (pt) |
CN (1) | CN102325548A (pt) |
AU (1) | AU2010215691B2 (pt) |
BR (1) | BRPI1008566A8 (pt) |
CA (1) | CA2750980A1 (pt) |
IL (1) | IL214255B (pt) |
MX (2) | MX349996B (pt) |
NZ (2) | NZ601793A (pt) |
SG (2) | SG173033A1 (pt) |
WO (1) | WO2010094490A1 (pt) |
ZA (1) | ZA201105472B (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1762575A1 (en) | 2005-09-12 | 2007-03-14 | Ganymed Pharmaceuticals AG | Identification of tumor-associated antigens for diagnosis and therapy |
EP1970384A1 (en) | 2007-03-14 | 2008-09-17 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
EP2166021A1 (en) * | 2008-09-16 | 2010-03-24 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
AU2015255252B2 (en) * | 2009-02-20 | 2017-11-23 | BioNTech SE | Methods and compositions for diagnosis and treatment of cancer |
NZ594480A (en) * | 2009-02-20 | 2013-11-29 | Ganymed Pharmaceuticals Ag | Methods and compositions for diagnosis and treatment of cancer |
AU2010318316B2 (en) | 2009-11-11 | 2016-01-14 | Astellas Pharma Inc. | Antibodies specific for Claudin 6 (CLDN6) |
EP2371864A1 (en) | 2010-03-23 | 2011-10-05 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
AU2012258087B2 (en) | 2011-05-13 | 2017-07-20 | Astellas Pharma Inc. | Antibodies for treatment of cancer expressing claudin 6 |
US9717781B2 (en) * | 2011-08-08 | 2017-08-01 | Alexander Shneider | Methods and compositions relating to P62 for the treatment and prophylaxis of cancer |
ES2813415T3 (es) * | 2011-08-10 | 2021-03-23 | Lankenau Inst Medical Res | Métodos y composiciones para el tratamiento de enfermedades autoinmunes e inflamatorias |
EP2875046B1 (en) | 2012-07-19 | 2020-02-26 | Amgen Inc. | Human btnl3 proteins, nucleic acids, and antibodies and uses thereof |
KR101329655B1 (ko) * | 2012-12-13 | 2013-11-14 | 강원대학교산학협력단 | 수압식 안마장치 및 그의 제어방법 |
EP2964672B1 (en) * | 2013-03-05 | 2019-10-09 | Board of Regents, The University of Texas System | Specific detection tool for mesenchymal and epithelial-mesenchymal transformed circulating tumor cells |
SG11201507496UA (en) | 2013-04-17 | 2015-11-27 | Pfizer | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
GB201312133D0 (en) * | 2013-07-05 | 2013-08-21 | Univ Birmingham | Immunotherapy |
WO2015014376A1 (en) | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
TWI777196B (zh) * | 2013-08-05 | 2022-09-11 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物(五) |
CN104634907B (zh) * | 2013-11-11 | 2018-04-20 | 上海交通大学医学院附属瑞金医院 | 一类氨基酸分子组合作为胃癌标志物的用途 |
CN110123837A (zh) * | 2018-02-02 | 2019-08-16 | 科济生物医药(上海)有限公司 | 细胞免疫治疗的组合 |
US20230310500A1 (en) * | 2020-09-03 | 2023-10-05 | Techno Craft Corporation Ltd. | Use of Immune Killer Cell Against Circulating Tumor Cells in Solid Tumor Treatment |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9019812D0 (en) | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
US5830755A (en) * | 1995-03-27 | 1998-11-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | T-cell receptors and their use in therapeutic and diagnostic methods |
US5677139A (en) | 1995-04-21 | 1997-10-14 | President And Fellows Of Harvard College | In vitro differentiation of CD34+ progenitor cells into T lymphocytes |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US5928631A (en) | 1997-06-09 | 1999-07-27 | The Procter & Gamble Company | Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins |
US20030166132A1 (en) * | 1998-08-26 | 2003-09-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU3479700A (en) * | 1999-02-22 | 2000-09-14 | Incyte Pharmaceuticals, Inc. | Genes associated with diseases of the colon |
AU2001249622B2 (en) | 2000-03-30 | 2007-06-07 | Massachusetts Institute Of Technology | RNA sequence-specific mediators of RNA interference |
CA2633413C (en) * | 2001-06-20 | 2012-08-21 | Genentech, Inc. | Antibodies against tumor-associated antigenic target (tat) polypeptides |
AT500651B9 (de) * | 2003-05-27 | 2010-04-15 | Altropus Gmbh | Aktiv immunisierender antikörper |
US20080305493A1 (en) | 2004-03-08 | 2008-12-11 | Avalon Pharmaceuticals | Determining Cancer-Linked Genes and Therapeutic Targets Using Molecular Cytogenetic Methods |
EP2060583A1 (en) * | 2007-10-23 | 2009-05-20 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
US20090258096A1 (en) * | 2008-04-11 | 2009-10-15 | Bionovo, Inc. | Anticancer Methods Employing Extracts of Gleditsia sinensis Lam |
NZ594480A (en) * | 2009-02-20 | 2013-11-29 | Ganymed Pharmaceuticals Ag | Methods and compositions for diagnosis and treatment of cancer |
EP2875046B1 (en) | 2012-07-19 | 2020-02-26 | Amgen Inc. | Human btnl3 proteins, nucleic acids, and antibodies and uses thereof |
-
2009
- 2009-02-20 EP EP09002458A patent/EP2221063A1/en not_active Withdrawn
-
2010
- 2010-02-18 NZ NZ601793A patent/NZ601793A/xx unknown
- 2010-02-18 CN CN2010800086568A patent/CN102325548A/zh active Pending
- 2010-02-18 KR KR1020117021992A patent/KR20110128315A/ko not_active Application Discontinuation
- 2010-02-18 SG SG2011051851A patent/SG173033A1/en unknown
- 2010-02-18 JP JP2011550479A patent/JP5809067B2/ja active Active
- 2010-02-18 NZ NZ594479A patent/NZ594479A/xx unknown
- 2010-02-18 BR BRPI1008566A patent/BRPI1008566A8/pt not_active IP Right Cessation
- 2010-02-18 WO PCT/EP2010/001035 patent/WO2010094490A1/en active Application Filing
- 2010-02-18 AU AU2010215691A patent/AU2010215691B2/en active Active
- 2010-02-18 EP EP16202946.6A patent/EP3170511A1/en not_active Withdrawn
- 2010-02-18 EP EP10705807A patent/EP2398497A1/en not_active Ceased
- 2010-02-18 CA CA2750980A patent/CA2750980A1/en not_active Abandoned
- 2010-02-18 MX MX2015016088A patent/MX349996B/es unknown
- 2010-02-18 US US13/201,726 patent/US9637548B2/en active Active
- 2010-02-18 MX MX2011008429A patent/MX2011008429A/es unknown
- 2010-02-18 SG SG10201402491YA patent/SG10201402491YA/en unknown
-
2011
- 2011-07-24 IL IL214255A patent/IL214255B/en active IP Right Grant
- 2011-07-25 ZA ZA2011/05472A patent/ZA201105472B/en unknown
-
2015
- 2015-09-10 JP JP2015178261A patent/JP2016040253A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3170511A1 (en) | 2017-05-24 |
JP2012518608A (ja) | 2012-08-16 |
MX2011008429A (es) | 2011-09-29 |
IL214255A0 (en) | 2011-09-27 |
US20110318264A1 (en) | 2011-12-29 |
KR20110128315A (ko) | 2011-11-29 |
SG173033A1 (en) | 2011-08-29 |
EP2398497A1 (en) | 2011-12-28 |
NZ601793A (en) | 2013-11-29 |
IL214255B (en) | 2018-05-31 |
MX349996B (es) | 2017-08-23 |
JP2016040253A (ja) | 2016-03-24 |
ZA201105472B (en) | 2012-10-31 |
CA2750980A1 (en) | 2010-08-26 |
WO2010094490A1 (en) | 2010-08-26 |
JP5809067B2 (ja) | 2015-11-10 |
EP2221063A1 (en) | 2010-08-25 |
AU2010215691B2 (en) | 2015-09-03 |
BRPI1008566A2 (pt) | 2017-06-06 |
NZ594479A (en) | 2013-06-28 |
CN102325548A (zh) | 2012-01-18 |
US9637548B2 (en) | 2017-05-02 |
AU2010215691A1 (en) | 2011-08-18 |
SG10201402491YA (en) | 2014-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI1008566A8 (pt) | métodos e composições para o diagnóstico e tratamento de câncer | |
BRPI1008564A2 (pt) | métodos e composições para o dignóstico e tratamento de câncer | |
BRPI1007972A2 (pt) | composições de combinação e métodos para o tratamento de câncer | |
BR112012004979A2 (pt) | composições para o tratamento de semente e métodos | |
BRPI0919238A2 (pt) | métodos e composições para o tratamento de câncer | |
BR112012005594A2 (pt) | tratamento de câncer | |
BRPI0813725A2 (pt) | Métodos e composições para tratamento de doenças | |
BRPI0921321A2 (pt) | métodos para o tratamento de indwcções e tumores | |
BRPI0909164A2 (pt) | método e composições para o tratamento de câncer | |
BR112012018947A2 (pt) | composição farmacêutica para tratamento e\ou prevenção do cancêr | |
BRPI0908026A2 (pt) | Métodos para o tratamento de doenças do intestino | |
BRPI1010874A8 (pt) | composição para o tratamento de câncer de próstata | |
BRPI0911112A2 (pt) | composições e métodos para o tratamento do câncer de mama | |
BRPI1007600A2 (pt) | composições e métodos para tratamento de doenças cardiovasculares | |
BRPI1011325A2 (pt) | composições e métodos para o tratamento de inflamação | |
SMT201700056B (it) | Fosfaplatine e relativo utilizzo per il trattamento di cancro | |
BRPI1007995A2 (pt) | orto-aminoamidas para o tratamento de cãncer. | |
BRPI0922884A2 (pt) | compostos para tratamento de câncer | |
BR112013011659A2 (pt) | métodos de tratamento do câncer | |
BRPI0812932A2 (pt) | Composições e métodos de tratar câncer | |
BRPI0922367A2 (pt) | enzastaurin para o tratamento de câncer | |
BRPI0810207A2 (pt) | Métodos e composições para o tratamento de câncer | |
BR112013028890A2 (pt) | composições e métodos para o tratamento de câncer | |
BRPI0907723A2 (pt) | Métodos e composições para o tratamento de doença respiratória | |
BRPI0918508A2 (pt) | orto-aminoanilidas para o tratamento de câncer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2501 DE 11-12-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |